Effects of a histamine type 2 receptor antagonist, BMY-26539-01, on equine gastric acid secretion.

This research studied the effects of a new histamine type 2 receptor antagonist (BMY-26539-01) on gastric acid secretion in horses. It found that the medicine increased the pH and decreased the hydrogen ion concentration in the horses’ stomachs in a dose-related schedule, with no adverse outcomes recorded.

Study Design

• The research aimed to test the impacts of BMY-26539-01, a newly created histamine type 2 receptor antagonist, on gastric acid release in fasted horses. The study was designed as a dose-response study where varying doses of the drug were administered to test its efficacy.
• The experiment was conducted on four fasted horses, and different doses of BMY-26539-01 (0.1 mg/kg, 0.3 mg/kg, 0.5 mg/kg) or a placebo were given in a randomly determined sequence to each horse.

Measurements and Results

• Through baseline measurements, the researchers observed that the hydrogen ion concentration and pH levels fluctuated in all four horses before the drug administration.
• However, following the administration of BMY-26539-01, the average pH levels in the horses went up, and the hydrogen ion concentration fell, and these changes followed a dose-related pattern. This means that higher doses of BMY-26539-01 caused a greater increase in pH level and a larger decrease in hydrogen ion concentration.
• At the doses of 0.3 mg/kg and 0.5 mg/kg, the increased pH levels persisted for greater than 4 hours and 8 hours respectively. This demonstrates that the drug’s effect was not only evident but also long-lasting.
• The study recorded no adverse effects from the administration of BMY-26539-01, suggesting that it is safe for use in horses.
• All statistical methods used in the study had a significant level of 0.01. This means that there was only a 1 percent chance that the results obtained were due to random occurrence, thus confirming the accuracy of the findings.

Significance of the Research

• This research provides promising evidence for the efficacy and safety of BMY-26539-01 in controlling gastric acid secretion in horses. The drug can potentially serve as an effective treatment for equine gastric problems, specifically those involving excessive gastric acid secretion.
• The significant level used for all statistical methods implies that the probability of the observed results being due to mere chance is very low. Therefore, the findings of the research carry a high level of reliability and validity.